McCarthy, T <br/><br/>
Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.  [electronic resource] 

 -  Journal of the peripheral nervous system : JPNS  Oct 2014 
 - S13-4 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1529-8027 
<br/><br/><label>Standard No.: </label>10.1111/jns.12080_4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Angiotensin II Type 2 Receptor Blockers--administration & dosage<br/>Benzhydryl Compounds--administration & dosage<br/>Clinical Trials, Phase II as Topic<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Isoquinolines--administration & dosage<br/>Male<br/>Multicenter Studies as Topic<br/>Neuralgia, Postherpetic--drug therapy<br/>Pain Measurement